


PHARMACEUTICAL 2018

ALNYLAM PHARMACEUTICALS INC. Alnylam 20 Rank 36 of 342





PHARMACEUTICAL 2018



The relative strengths and weaknesses of ALNYLAM PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALNYLAM PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of ALNYLAM PHARMACEUTICALS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 184% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	1,764,740
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	144,251
Liabilities, Non-Current	4,347
Other Assets	48,090
Other Compr. Net Income	-992
Other Expenses	0
Other Liabilities	79,701
Other Net Income	99,126
Other Revenues	0
Property and Equipment	181,900
Research and Development	390,635
Selling, General and Administrative Expense	199,365

Output Variable	Value in 1000 USD
Assets	1,994,730
Liabilities	228,299
Expenses	590,000
Revenues	0
Stockholders Equity	1,766,431
Net Income	-490,874
Comprehensive Net Income	-491,370
Economic Capital Ratio	229%

